Tag
22 articles
Anthropic's Claude language model has demonstrated the ability to design proteins with a 35% hit rate in drug development, outperforming industry standards. The breakthrough could democratize protein design for labs worldwide.
Novo Nordisk and AWS have partnered to integrate agentic AI into drug discovery, aiming to accelerate the development of new therapies through advanced AI tools and a co-innovation hub in London.
Google's top AI researchers, including Jeff Dean, have left to found Discovery Loop, a startup focused on using AI for breakthrough discoveries in drug development, chip design, and scientific research.
Relation Therapeutics is tackling the data scarcity issue in AI-driven biology by manufacturing the datasets needed to train AI models of the cell. GSK has committed up to $110 million to support this effort.
Insilico Medicine has significantly shortened drug discovery timelines in China by combining AI with laboratory research, cutting development time to as little as nine months.
Bristol Myers Squibb has acquired Nvidia's DGX SuperPOD based on the Vera Rubin architecture, becoming the first life sciences company to do so. The system will accelerate drug discovery and development through advanced AI capabilities.
AWS GraphRAG deployment has slashed drug research cycles by 87% by unifying fragmented databases into a single queryable knowledge graph. This advancement significantly accelerates the early stages of drug discovery and improves success rates.
British startup Orbital Assembly Corporation has launched a longevity lab into orbit to collect protein behavior data for AI training, potentially revolutionizing disease prediction and drug development.
This article explains how artificial intelligence (AI) is revolutionizing drug discovery, especially for neglected diseases. Learn how AI can speed up the process of finding new medicines and make treatments more accessible to people with rare conditions.
NVIDIA's new BioNeMo Agent Toolkit turns biomolecular models into callable AI skills, significantly boosting task completion rates in drug discovery.
OpenAI and Molecule.one demonstrate how an AI chemist using GPT-5.4 improved a key drug-making reaction, advancing medicinal chemistry research.
Reid Hoffman is leaving Microsoft’s board to focus on his AI drug discovery startup, Manus. His departure marks a shift from corporate governance to hands-on entrepreneurship.
